TAVR Anticoagulation With Apixaban Not Superior to Standard Care
Oral anticoagulation reduces clot formation around the implanted valve with no increased bleeding risk
May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from a new trial called ATLANTIS presented at the American College of Cardiology (ACC) 2021 virtual scientific session. Researchers found that while apixaban reduced the formation of thrombosis around the implanted valve with no increased bleeding risk, a subset of patients taking apixaban who did not have an indication for anticoagulation apart from the TAVR procedure showed a tendency toward a higher rate of non-cardiovascular death, a finding researchers said deserves further exploration.

For the whole article:
https://www.dicardiology.com/content/tavr-anticoagulation-apixaban-not-superior-standard-care